<DOC>
	<DOCNO>NCT03057938</DOCNO>
	<brief_summary>Phase II , open-label clinical trial medicinal product . A total 30 subject include study . All participant receive single intravenous dose 300 MBq FBB . A 20-minute PET image acquire start approximately 90 minute intravenous injection FBB . The present proposal aim : ass safety single dose FBB follow PET scan individual subjective cognitive decline ( SCD ) , determine number SCD subject positive visual FBB-PET scan , determine number SCD subject positive standardized uptake value ratio ( SUVRs ) FBB-PET scan explore cortical pattern amyloid deposition SCD subject .</brief_summary>
	<brief_title>Subjects With Subjective Cognitive Decline : 18F-Florbetaben Positron Emission Tomography Study</brief_title>
	<detailed_description>statistical method : Primary outcome For analysis primary outcome , descriptive statistical approach implement , calculate proportion adverse event proportion SCD subject positive FBB-PET visual assessment 9.2 Data Management Demographical neuropsychological data enter data base . Statistical analysis perform SPSS software Windows ( v.22.0 ) . Sample size A sample size 30 subject estimate . Since proof-of-concept study , assumption base previously publish data . Statistical significance adjustment multiplicity The analysis carry accord principle ICHE9 Guide accordance recommendation CPM/EWP/908/99 Points Consider Multiplicity issue Clinical Trials . The contrast carry Error Type 5 bilateral I . In case , since exploratory study , adjustment multiplicity . Criteria discontinuation The study complete two premise meet : - Inclusion number patient need sample size - End clinical monitoring No interim analysis plan .</detailed_description>
	<mesh_term>Cognition Disorders</mesh_term>
	<criteria>Participants must commit participate complete study procedure . The patient must report memory problem ( isolation combination complaint domains ) concern . Age ≥ 60 MiniMental State Examination cutoff inclusion ≥ 26 . Clinical Dementia Rating &lt; 0,5 . Subjects must sign Informed Consent Form voluntarily participate study . Subjects able complete study . Any major disease history major disease , especially hepatobilliar disease ( AST /ALT ≥ 5 x ULN ) advance renal insufficiency ( creatinine ≥ 2 x ULN ) . Current previous history alcohol abuse epilepsy . Allergic Florbetaben constituent . Multiple drug allergy and/or previous history contrast allergy . Any disease history disease , opinion investigator , cause disturbance brain function ( e.g . vitamin B12 folic acid deficiency , disturb thyroid function ) . Evidence neurological psychiatric disease , eg . parkinsonism , history stroke seizure . Pregnancy breast feed plan pregnancy study period .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Alzheimer</keyword>
	<keyword>Subjective Cognitive Decline</keyword>
	<keyword>Florbetaben</keyword>
</DOC>